Incyte Co. (NASDAQ:INCY) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 104.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 327,272 shares of the biopharmaceutical company's stock after purchasing an additional 166,857 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.17% of Incyte worth $22,605,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of INCY. Crossmark Global Holdings Inc. boosted its stake in shares of Incyte by 1.1% during the third quarter. Crossmark Global Holdings Inc. now owns 25,079 shares of the biopharmaceutical company's stock worth $1,657,000 after buying an additional 276 shares during the period. Venturi Wealth Management LLC acquired a new stake in Incyte during the 3rd quarter worth approximately $65,000. GSA Capital Partners LLP lifted its position in Incyte by 26.5% during the 3rd quarter. GSA Capital Partners LLP now owns 6,453 shares of the biopharmaceutical company's stock worth $427,000 after acquiring an additional 1,351 shares during the period. Haverford Trust Co grew its stake in shares of Incyte by 1.8% in the 3rd quarter. Haverford Trust Co now owns 7,796 shares of the biopharmaceutical company's stock valued at $515,000 after purchasing an additional 135 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Incyte by 21.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,406 shares of the biopharmaceutical company's stock valued at $423,000 after purchasing an additional 1,145 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Incyte

In other Incyte news, insider Thomas Tray sold 650 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $69.31, for a total value of $45,051.50. Following the completion of the transaction, the insider now directly owns 23,312 shares in the company, valued at approximately $1,615,754.72. The trade was a 2.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sheila A. Denton sold 14,069 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,914,561.36. This trade represents a 35.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,320 shares of company stock valued at $2,072,849. 17.60% of the stock is owned by insiders.

Incyte Trading Down 4.3 %

NASDAQ:INCY opened at $68.07 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $13.17 billion, a PE ratio of 252.12, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76. The stock has a fifty day simple moving average of $71.85 and a 200-day simple moving average of $70.29. Incyte Co. has a 52-week low of $50.35 and a 52-week high of $83.95.

Remove Ads

Incyte (NASDAQ:INCY - Get Free Report) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities research analysts expect that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Wells Fargo & Company increased their price target on Incyte from $68.00 to $70.00 and gave the stock an "equal weight" rating in a report on Thursday, December 19th. Citigroup reduced their target price on shares of Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada lowered their target price on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a report on Tuesday, February 11th. StockNews.com cut shares of Incyte from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus lifted their price objective on Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $75.25.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.